Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trichlorethanol SCHEMBL325071 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL7261325 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL291748 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL759616 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL1436780 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL8522341 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL16162174 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL4450822 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL88329 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL6898269 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102772501-A | Rheum emodi Wall. extract and its preparing method | TIBET JINHADA PHARMACEUTICAL CO LTD | 2012-11-14 | — | — | CN | claimed |
| CN-108137638-B | Bridged nucleic acid GuNA, method for producing same, and intermediate compound | 田边三菱制药株式会社 | 2022-05-03 | — | — | CN | disclosed |
| US-10961269-B2 | Bridged nucleic acid GuNA, method for producing same, and intermediate compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-03-30 | — | — | US | disclosed |
| CN-108003119-B | Method for synthesizing cabazitaxel from 10-deacetylbaccatin III | 云南汉德生物技术有限公司 | 2020-04-24 | — | — | CN | disclosed |
| US-20180251488-A1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-09-06 | — | — | US | disclosed |
| EP-3351548-A1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-07-25 | — | — | EP | disclosed |
| CN-108137638-A | Bridging type nucleic acid GuNA, its manufacturing method and midbody compound | 田边三菱制药株式会社 | 2018-06-08 | — | — | CN | disclosed |
| CN-108047749-A | Colored resin composition, color filter, liquid crystal display device, and organic E L display device | 三菱化学株式会社 | 2018-05-18 | — | — | CN | disclosed |
| CN-103430099-B | colored resin composition, color filter, liquid crystal display device, and organic E L display device | 三菱化学株式会社 | 2018-02-13 | — | — | CN | disclosed |
| EP-2374802-B1 | KYNURENINE PRODUCTION INHIBITOR | KYOWA HAKKO KIRIN CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| CN-1423635-A | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CHEMICAL IND CO LTD (JP) | 2003-06-11 | — | — | CN | disclosed |
| EP-1273571-A1 | NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME | Kureha Chemical Industry Co., Ltd. (JP) | 2003-01-08 | — | — | EP | disclosed |
| CN-1093124-C | Substituted 4-hydroxy-phenylalcanoic acid derivatives with activity to ppar-'gamma' | GLAXO GROUP LTD (GB) | 2002-10-23 | — | — | CN | disclosed |
| EP-0863141-B1 | SUBSTITUTED HETEROAROMATIC DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2001-09-12 | — | — | EP | disclosed |
| US-6130232-A | Substituted piperidine derivatives as muscarinic M3 receptor antagonists | BANYU PHARMACEUTICAL COALTD (JP) | 2000-10-10 | — | — | US | disclosed |
| CN-1218460-A | Substituted 4-hydroxy-phenylalcanoic acid derivatives with activity to ppar-'gamma' | GLAXO GROUP LTD (GB) | 1999-06-02 | — | — | CN | disclosed |
| CN-1211244-A | Radicicol derivatives | KYOWA HAKKO KOGYO KK (JP) | 1999-03-17 | — | — | CN | disclosed |
| EP-0863141-A1 | SUBSTITUTED HETEROAROMATIC DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-09-09 | — | — | EP | disclosed |
| EP-0161436-B1 | REDOX INDICATORS | Roche Diagnostics GmbH (DE) | 1987-09-02 | — | — | EP | disclosed |
| EP-0161436-A1 | Redox indicators | Roche Diagnostics GmbH (DE) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961269-B2 | Bridged nucleic acid GuNA, method for producing same, and intermediate compound | POLRMT, POLM, NSUN2 | LMNA 445/4885TDP1 150/4885TP53 862/4885 |
| US-20180251488-A1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | NSUN2, RNMT, POLRMT | LMNA 665/4885TDP1 190/4885TP53 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.